Trial ID or NCT#

NCT01088048

Status

not recruiting iconNOT RECRUITING

Purpose

The primary objective of the study is to evaluate the safety of idelalisib in combination with an anti-CD20 monoclonal antibody (mAb), a chemotherapeutic agent, a mammalian target of rapamycin (mTOR) inhibitor, a protease inhibitor, an antiangiogenic agent, and/or an immunomodulatory agent in participants with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL).

Official Title

A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Steven Coutre
Steven Coutre
Hematologist, Leukemia specialist
Rondeep Brar
Rondeep Brar
Hematologist, Leukemia specialist, Medical oncologist
Clinical Associate Professor, Medicine - Hematology
Lauren Maeda
Lauren Maeda
Medical oncologist, Hematologist, Lymphoma specialist
Clinical Associate Professor, Medicine - Oncology Clinical Assistant Professor, Medicine - Hematology
Caroline Berube
Caroline Berube
Hematologist
Clinical Associate Professor, Medicine - Hematology
Jason Gotlib
Hematologist, Medical oncologist, Leukemia specialist
Professor of Medicine (Hematology)

Contact us to find out if this trial is right for you.

CONTACT

Cancer Clinical Trials Office
(650) 498-7061